FIELD: pharmacy. SUBSTANCE: composition has pharmaceutically effective amount of medicinal or diagnostic agent and the following components, mas. /vol. %: methylcellulose containing methoxyl-groups at the range 26-33%, 0.2-2.1; citric acid, 1.2-2.3; polyethylene glycol (average molecular mass is 300-50000 Da), 0.5-13; and pharmaceutically acceptable agent for pH value control. Composition has pH from 3 to 10. Composition is a liquid before administration and forms gel at body temperature immediately after administration or use. Composition provides bioavailability of pharmaceutically effective component and maintains effect of medicinal agents for the long period. Composition can be used in ophthalmology, dermatology and for body cavity treatment. EFFECT: enhanced effectiveness of composition. 12 cl, 2 dwg, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL COMPOSITION FOR GLAUCOMA TREATMENT | 1993 |
|
RU2102069C1 |
HEAT-SENSITIVE GEL-FORMING ARTIFICIAL TEAR | 2018 |
|
RU2710366C1 |
ANTI-INFLAMMATORY OPHTHALMIC DROPS | 1995 |
|
RU2136252C1 |
PHARMACEUTICAL COMPOSITION FOR TOPICAL USE FOR TREATMENT OF EYE AND NOSE ALLERGIC DISEASES | 1993 |
|
RU2130774C1 |
METHOD OF PREPARING AN AQUEOUS SUSPENSION AND AN AQUEOUS OPHTHALMIC PREPARATION | 1992 |
|
RU2098094C1 |
WATER-BASED LIQUID COMPOSITION CONTAINING AMIDE COMPOUND | 2007 |
|
RU2476219C2 |
ANTIALLERGIC PHARMACEUTICAL COMPOSITION FOR LOCAL OCULAR APPLICATION AND METHOD FOR ITS PRODUCTION | 1994 |
|
RU2107497C1 |
TETRAZOLE DERIVATIVES, METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION INHIBITING ALDOSE REDUCTASE | 1990 |
|
RU2097381C1 |
DERIVATIVES OF INDOLE AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF | 1999 |
|
RU2212404C2 |
PREVENTIVE AND THERAPEUTIC AGENT FOR POSTERIOR EYE DISEASES | 2008 |
|
RU2470635C2 |
Authors
Dates
1998-04-10—Published
1993-11-10—Filed